Close the window Close the window
 

Instructions

Name
Vnr
Strength
Dosage form
Pack size
Pharmaceutical company
Price
Active substance
Reimbursability
Generic equivalents
Reference price
ATC kode
Limited prescribing rights

Name
Trade name of the product and an indication whether the product is a prescription medicine, over-the-counter medicine, clinical nutrient, emollient cream or a medicine dispensed under a temporary special license. If there are restrictions on direct reimbursement or generic substitution, this will be indicated in brackets under the name of the product (e.g., no generic substitution with antiepileptics).

Vnr
The Nordic Article Number (Vnr) is a six-digit code identifying packaged pharmaceuticals with marketing authorisation. No Nordic Article Number is assigned to clinical nutrients, emollients or pharmaceuticals that may be released for consumption under a temporary special licence from the Finnish Medicines Agency (Fimea).

'Being phased out' in the Vnr column means that the product in question is no longer available at wholesale but may still be available from certain pharmacies.

Strength
Amount of active substance contained in the product. This field can also include additional information on the package such as the type of package or included dispenser. This information is recorded in the Pharmaceutical Database in Finnish only.

Dosage form
Dosage form of the product, for example tablet, cream or solution for injection. This information is recorded in the Pharmaceutical Database in Finnish and Swedish only.

Pack size
Amount of product included in the package. This field also indicates the type of packaging, such as bottle or blister pack. This information is recorded in the Pharmaceutical Database in Finnish and Swedish only.

Pharmaceutical company
Name of the marketing authorisation holder or manufacturer.

Price
All prices shown are retail prices (including 10% VAT).

A dispensing fee is added to the price of prescribed medicines, emollient creams and clinical nutritional products at the pharmacy. The rates are

If the pharmacy dispenses several packages of the product at the same time, the dispensing fee is only charged once. If the dispensed product is covered by the reimbursement system, the customer is paid a reimbursement also for the dispensing fee.

Rules governing the determination of retail prices and the pharmacy dispensing fee are found in the Council of State decree on drug tariffs.

Active substance
Active substance(s) of the medicinal product. This information is recorded in the Pharmaceutical Database in Finnish and Swedish only.

Reimbursability
Reimbursability information is indicated by an abbreviation, which is linked to more detailed information on reimbursability. The abbreviations used in the table are

Non - product is not reimbursable
Basic - product has basic reimbursement coverage
Special - product has basic and/or special reimbursement coverage

Generic equivalents
The arrowhead links to a list of the generic equivalents.

Generic equivalents contain the same active substance in the same amount as the substitutable product, and their biological equivalence has been proven. A list of substitutable medicinal products is published quarterly by the Finnish Medicines Agency (Fimea).

The pharmacy will substitute a prescribed product with the least expensive generally available substitutable product or one which is only marginally different in price from the least expensive alternative, unless substitution is prohibited by the prescriber or the customer.

The lowest price and the price only marginally different from the lowest price for substitutable medicinal products (the difference between these two prices constituting the price corridor), are determined on the basis of the prices reported by pharmaceutical companies to Kela. For a group of interchangeable medicinal products, the lowest price is the VAT-inclusive retail price of the least expensive product on the first day of the quarter or, where an applicable reference price group exists, the VAT-inclusive retail price of the least expensive reimbursable product in the reference group.

A medicinal product is considered to be ‘marginally different in price’ if the price difference to the least expensive product is no more than €0.50.

Reference price
For products belonging to a reference price group, the basis of reimbursement is the reference price, which is determined quarterly based on notifications submitted by the pharmaceutical companies to the Pharmaceuticals Pricing Board.

A reference price group consists of the medicinal products that are substitutable with each other. The group must include at least one reimbursable generic, parallel import or parallel distribution product. The reference price is calculated by adding €0.50 to the VAT-inclusive retail price of the least expensive product in the reference price group.

For products belonging to a reference price group, the price used as the basis of reimbursement may not exceed the reference price. Any difference must be paid by the customer. The pharmacy may, with the customer’s consent, substitute the prescribed product with a product available at or below the reference price. If substitution is prohibited by the prescriber on medical or therapeutic grounds, the reimbursement is calculated on the basis of the actual price.

ATC code
For products belonging to a reference price group, the basis of reimbursement is the reference price, which is determined quarterly based on notifications submitted by the pharmaceutical companies to the Pharmaceuticals Pricing Board.

Limited prescribing rights
Products with the text ‘Under certain conditions, may also be prescribed by a nurse’ in the Reimbursability display are governed by specific rules on limited non-physician prescribing. They may be prescribed not only by a doctor but also by a registered nurse, public health nurse or midwife. Limited prescribing rights are conditional on written authorisation from the chief physician of the health care centre or hospital district.

Additional information: Decree of the Ministry of Social Affairs and Health concerning the prescribing of medicines (sosiaali- ja terveysministeriön asetus lääkkeen määräämisestä/social- och hälsovårdsministeriets förordning om förskrivning av läkemedel) (1088/2010). An appendix to the Decree specifies the products which nurses are allowed to prescribe and indicates whether a nurse can initiate the medication or merely continue a course of pharmaceutical treatment initiated by a doctor.

Top of page